Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx věcí,

kterým xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx generální xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx rok 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx ve xxxxxx.

X xxxxx xxxxxx Přílohy X vyslovil xxxxxxx Xxxxxxxxx České xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx I xxxxxxxxx x platnost x souladu x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x nahradilo Přílohu X pro rok 2023, platnou xx 1. xxxxx 2023, xxxxx vstoupila x xxxxxxxx xxx Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx vyhlášena xxx č. 32/2023 Sb. m. s.

Xxxxxxxx znění Xxxxxxx X xxx xxx 2024 x její xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. JUDr. Xxxxxx, Ph.D., XX.X., x. r.

vrchní xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx

Xxxx

Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx v xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam xx xxxxxx od 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x metod xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx v xxxxxxxxxx x francouzštině. X případě jakýchkoliv xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx pojmy xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx xxxxx a xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx daný xxxxx xxxxxxxxxxx jiné xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx xxxxxxxxxxx xxxxx před xxxxxxx (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx do konce Xxxxxxx a procesu xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, jak je xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „pro xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Xxxxx Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx méně nebezpečné xxx xxxx xxxxxxxxx xxxxx xxxx metody. Xxx xxxxx o xxxxx x metody, xxxxx Xxxxxxxxx pravděpodobně xxxx xxxx použil x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx výkonu.“

Návykové xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx látky, xxxxx jsou xxxx xxxxxx xxxxxxxx x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx společnosti xxxx rámec xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxx xxxxx: kokain, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 NESCHVÁLENÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není v xxxxxxxx době xxxxxxxxx xxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx použití x xxxx (xxxx. xxxxxx x předklinickém xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj byl xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx pouze xxx veterinární xxxxxxx), xx zakázána xxxxx.

Xxxx xxxxx zahrnuje xxxxx xxxxxxx xxxxx, mimo xxxx BPC-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (xxxx. Xxxxxxxxxxx x Xxxxxxxxxx).

X1 ANABOLICKÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx jsou zakázány.

S1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx xxxxxxxxx podání, xxxx xxxx včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion)		•	furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)		•	metandriol
•	7ɑ-hydroxy-DHEA		•	metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on)
•	7-keto-DHEA		•	metylklostebol
•	11ß-metyl-19-nortestosteron		•	metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on)		•	nandrolon (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (androsta-1,4-dien-3,17-dion)		•	oxandrolon
•	calusteron		•	oxymesteron
•	klostebol		•	oxymetolon
•	danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx včetně:

Clenbuterol, osilodrostat, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, enobosarm (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky v xxxx xxxxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx látky x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); sloučeniny xxxxxxxx na EPO, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx prostředky x xxxxxx sloučeniny, např. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (BAY 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (CEPO).

S2.2. XXXXXXXXX XXXXXXX X XXXXXX UVOLŇUJÍCÍ XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, xxxx xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (CG),

• xxxxxxxxxxxx xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxxxx, deslorelin, goserelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Růstový hormon (XX), jeho xxxxxxx x xxxxxxxxx, xxxx xxxx včetně:

• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, např. AOD-9604 x xXX 176–191.

X2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, mimo xxxx xxxxxx:

• hormon xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,

• xxxxxxxxxxx růstového hormonu (XXX) x jejich xxxxxxxx [např. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx a tabimorelin],

• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), GHRP-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, GHRP-5 a XXXX-6].

X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx včetně:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx růstový xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x jeho xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• xxxxxxxx-β4 x xxxx deriváty, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx modulátory xxxxxxxxx xxxxxxx ovlivňující xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití energie, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 AGONISTÉ

ZAKÁZANÉ XXXXX (XXX XXXXXXX X MIMO SOUTĚŽ)

Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx selektivní x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx všech xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x oddělených dávkách, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx jakékoliv dávce;

• xxxxxxxxx formoterol: maximálně xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 mikrogramů za 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxx xxxxxx xxx 1000 xx/xx nebo xxxxxxxxxxx x xxxxxxxx xxxxxx než 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx látky a xxxx xxxxxxxxxx za Xxxxxxxxx laboratorní xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx do xxxx xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxxx látky ve xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx do xxxx S4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx jsou xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx včetně:

•	2-androstenol (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX LÁTKY [XXXXXXXXXXXXX A SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX ZABRAŇUJÍCÍ XXXXXXXX RECEPTORU AKTIVINU XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx aktivin X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx nebo xxxxxx xxxxxxx myostatinu
	- xxxxxxx xxxxxxxxx aktivinu (xxxx. XXX-031)			- xxxxxxxx xxxxxx myostatin (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx aktivinu XXX (xxxx. bimagrumab)			- xxxxxxxxxx neutralizující xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, stamulumab)

S4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (AMPK), např. XXXXX, xxxxxxxx peroxizomovými xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, GW501516) x xxxxxxxx Rev-erbɑ , např. XX9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX A XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Diuretika, xxxx např.:

acetazolamid; amilorid; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; spironolakton; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Vaptany, xxxx. xxxxxxxxxx, mozavaptan, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• drospirenon; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx podání xxxxxxxxxxx x xxxxx anestezii.

POZNÁMKA

Nález xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: u formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Sportovce xxxxxxxx xxxx případně Xxx Soutěži xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxxxxxx v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx xxxxx xxxxx k xx, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx metody v xxxx xxxxx xxxx Xxxxxxxxxxxx x výjimkou xxxxx v X2.2, xxx jsou Specifické xxxxxx.

X1. XXXXXXXXXX X XXXX X KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, allogenní (homologní) xxxx heterologní krve xxxx produktů x xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx xx oběhového xxxxxxx x xxxxxxxx xxxxxxxx plazmy nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy provedené x registrovaném xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x výjimkou xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví xxxx x xxxxxxxx komponentami xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.

X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx x podvod xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx odebraných při Xxxxxxxxx xxxxxxxx.

Xxxx jiné xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx než xxxxxx 100 ml xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx nebo klinických xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx potencionálního xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:

M3.1. Xxxxxxx xxxxxxxxxx kyselin nebo xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx sekvence xxxxxx x/xxxx exprese xxxx jakýmkoliv mechanismem. Xx mimo xxxx xxxxxxxx technologie úprav xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx normálních xxxx geneticky modifikovaných xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Specifické xxxxx x xxxxxxxx xxxxx xxxxxxxxx v X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx látky x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, včetně všech xxxxxxxxx izomerů, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

S6.A: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx není xxxxxxxx uveden x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, BMPEA)		•	famprofazon		•	oktopamin
•	3-metylhexan-2-amin (1,2-dimetylpentylamin)		•	fenbutrazát		•	oxilofrin (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon a xxxx xxxxxxx, např. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (dimetylamfetamin)		•	metylendioxymetamfetamin		•	selegilin
•	efedrin3)		•	metylefedrin3)		•	sibutramin
•	epinefrin (adrenalin)4)		•	metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát]		•	solriamfetol
•	etamivan		•	metylfenidát		•	strychnin
•	etylfenidát		•	niketamid		•	tenamfetamin (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další látky x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx kožního, xxxxxxx, očního nebo xxxxxx použití (např. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x stimulancia zařazená xx Xxxxxxxxxxxxxx programu 2024⁵⁾.

X7 NARKOTIKA

ZAKÁZANÉ PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x této xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. d- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x jeho xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx přírodní x xxxxxxxxxx kanabinoidy xxxx zakázané, např.

• x xxxxxx (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx tetrahydrokanabionoly (THC)

• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx zakázány, pokud xxxx xxxxxxxx jakoukoliv xxxxxxxx, perorální [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx acetonid
•	kortizon		•	hydrokortizon
•	deflazakort		•	metylprednisolon

POZNÁMKA

• Xxxx xxxxxxx xxxxxx (včetně xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, intranazálního, xxxxxxxxxxxxxxxx, xxxxxx a xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx xx xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx indikací.

P1 BETA-BLOKÁTORY

ZAKÁZANÉ X URČITÝCH XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.

Beta-blokátory xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx x kde xx xx označeno xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – skoky xx xxxxxx, xxxxxxxxxxx xxxxx / U-rampa x xxxxxxxxx X-xxxxx / xxx xxx

• xxxxxxxxxxxx xxxxx (XXX)

• podvodní xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx a xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• šipky (XXX)

• xxxx (XXX)

• minigolf (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx také Xxxx soutěž

Mimo xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx v xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x jeho x-xxxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx x moči vyšší xxx 5 mikrogramů x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx vyšší než 150 mikrogramů x 1 ml.

³⁾ xxxxxxx x metylefedrin: zakázány xxx koncentraci x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 ml.

⁴⁾ epinefrin (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx a xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx považovány xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx předpis x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx netýká xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx